Improved QoL Measured by SNOT-22 | DUPIXENT® (dupilumab)

SINUS-52 SNOT-22 SCORE REDUCTION THROUGH WEEK 52

59%

IMPROVEMENT

with DUPIXENT (baseline score 50.16) vs 17% improvement with placebo (baseline score 53.48) (LSM difference: -20.96 [95% CI: -25.03, -16.89])¹

DUPIXENT 300 mg Q2W +
INCS (n=150)
Placebo + INCS (n=153)

LSM change
from baseline
in SNOT-22
total score

0
-5
-10
-15
-20
-25
-30
-35

Weeks

54%

SNOT-22 SCORE IMPROVEMENT AT WEEK 24 with DUPIXENT 300 mg Q2W + INCS (n=295, pooled DUPIXENT
arms) (-27.77 from a baseline score of 51.02) vs 19% improvement with placebo + INCS (n=153) (-10.40 from
a baseline score of 53.48) (LSM difference: -17.36 [95% CI: -20.87, -13.85]) in SINUS-52¹

39%

SNOT-22 SCORE IMPROVEMENT SEEN AS EARLY AS WEEK 4 with DUPIXENT 300 mg Q2W + INCS (n=295,
pooled DUPIXENT arms) (-19.77 from a baseline score of 51.02) vs 16% improvement with placebo + INCS
(n=153) (-8.35 from a baseline score of 53.48) (LSM difference: -11.41 [95% CI: -14.78, -8.05]) in SINUS-52¹

Turn to DUPIXENT to improve a range of CRSwNP symptoms and QoL measures²

Turn to DUPIXENT to improve a range of CRSwNP symptoms
and QoL measures²

22-item Sino-Nasal Outcome Test (SNOT-22) score (range 0 to 110): reduced score indicates improvement.

^a SNOT-22 includes 22 items assessing symptoms and symptom impact associated with CRSwNP. SNOT-22 had a 2-week recall period. The meaningful clinically important difference is 8.9.

QoL, quality of life.

SEE NSAID-ERD RESULTS

BACK TO NASAL POLYPS SCORE

Explore the Safety Data
and Study Designs

View Safety Data SEE THE FULL STUDY DESIGNS

Rapid and sustained relief of
symptoms and improved quality
of life, as measured by SNOT-22

DUPIXENT Significantly Decreased SNOT-22 Score vs Placebo as
Early as Week 4, With Continued Improvement at Weeks 24 and 52
(Key Secondary Endpoints)^1,a

Explore the Safety Data
and Study Designs

Dosage and
Administration

Rapid and sustained relief of symptoms and improved quality of life, as measured by SNOT-22

DUPIXENT Significantly Decreased SNOT-22 Score vs Placebo as Early as Week 4, With Continued Improvement at Weeks 24 and 52 (Key Secondary Endpoints)1,a

Explore the Safety Data and Study Designs

Dosage and Administration

Are you sure you want to leave?

Rapid and sustained relief of
symptoms and improved quality
of life, as measured by SNOT-22

DUPIXENT Significantly Decreased SNOT-22 Score vs Placebo as
Early as Week 4, With Continued Improvement at Weeks 24 and 52
(Key Secondary Endpoints)^1,a

Explore the Safety Data
and Study Designs

Dosage and
Administration